MDGL vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 27, 2026

MDGL

57.8
AI Score
VS
MDGL Wins

MRNA

40.7
AI Score

Investment Advisor Scores

MDGL

58score
Recommendation
HOLD

MRNA

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MDGL MRNA Winner
Revenue 675.59M 534.00M MDGL
Net Income -152.33M -2.13B MDGL
Net Margin -22.5% -397.9% MDGL
Operating Income -149.03M -2.20B MDGL
ROE -29.1% -31.4% MDGL
ROA -12.2% -19.4% MDGL
Total Assets 1.24B 10.96B MRNA
Cash 292.73M 1.72B MRNA
Debt/Equity 0.65 0.09 MRNA
Current Ratio 3.20 2.29 MDGL
Free Cash Flow -152.21M -1.25B MDGL

Relative Price Performance (Last 90 Days)

MDGL 1M: -7.2% · 3M: -5.4% MRNA 1M: +22.5% · 3M: +136.9%

Current Technical Phase

MDGL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.8%), weak momentum, RSI 37

RSI (14): 36.8 · Price: $499.71

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.5% over 20 days), RSI 66

RSI (14): 65.8 · Price: $188.94

Fundamentals Snapshot

Metric MDGL MRNA
Market Cap — —
Forward P/E 51.9 -39.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.7% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin -0.2% -5.6%
EPS -13.98 -7.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MDGL is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.